CRISPR Therapeutics AG is a Switzerland-based gene-editing company. Innovative companies are trying to ensure that CRISPR Therapeutics' foothold in gene editing doesn't last forever. CRISPR Therapeutics is not responsible for the content or availability of third-party sites. Our therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing technology called CRISPR-Cas9. CRISPR Therapeutics AG (NASDAQ:CRSP) was the target of a significant drop in short interest during the month of December. Analisi Crispr Therapeutics CRSP - CH0334081137: Grafico di Analisi Tecnica, andamento nel tempo, resistenza, analisi fondamentale, prezzo, volume e open interest. View open opportunities, © 2021 CRISPR Therapeutics. As of December 31st, there was short interest totalling 3,610,000 shares, a drop of 16.2% from the December 15th total of 4,310,000 shares. CRISPR Forward-Looking StatementThis press release may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Dr. Ho in this press release, as well as regarding CRISPR Therapeutics’ expectations about any or all of the following: (i) the expected benefits of CRISPR Therapeutics’ research funded by the Bill & Melinda Gates Foundation and (ii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Is the stock CRISPR Therapeutics is soaring to new highs today.I last looked at CRSP back on October 5 and wrote that, "I am not yet convinced that CRSP can rally … You are cautioned that forward-looking statements are inherently uncertain. … Prezzi in tempo reale gratuiti, ordini e Forum. Last year, Feng Zhang, one of the pioneering minds behind CRISPR gene-editing technology, and a number of colleagues launched yet another startup in the space called Beam Therapeutics… Learn about our current clinical research and trials in hemoglobinopathies and oncology below. Trades of CRSP Made In ARKK. CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress. CRISPR Therapeutics AG (1CG:BRN) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more. On Dec. 22 we looked at CRSP and concluded that, "if you are still long CRSP then … Expanded Access to Investigational Medicines, Download CRISPR Therapeutics Corporate Presentation. As of December 31st, there was short interest totalling 3,610,000 shares, a drop of 16.2% from the December 15th total of 4,310,000 shares. Ma l’euforia non dura molto e il crollo dovuto alla crisi della pandemia in corso, porta il titolo a toccare i 33,68 dollari a marzo 2020. At the close of trading, the stock’s price was $173.23, to imply an increase of 1.85% or $3.15 in intraday trading. Video. Four analysts have issued estimates for CRISPR Therapeutics’ earnings. The … While CRISPR Therapeutics, Fate Therapeutics and Editas have a Zacks Rank #3 (Hold), Intellia has a Zacks Rank #4 (Sell). You can see the complete list of … And in November, we took 155% long-term gains in Intellia Therapeutics NTLA. CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease. Dec 05, 2020. Editas has filed request with the … CRISPR Therapeutics AG (NASDAQ:CRSP)’s traded shares stood at 2,483,669 during the last session, with the company’s beta value hitting 2.35. The founders set out with an intention to engineer the very best CRISPR platform, with a bold leap from CRISPR discovery to CRISPR … Date. The mission of CRISPR Therapeutics is to develop transformative gene-based medicines for patients with serious diseases. Visualizza la serie di opzioni di base di CRSP e confronta le opzioni di CRISPR Therapeutics AG su Yahoo Finanza. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Contact Us . -Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based therapies for HIV that can benefit patients worldwide-. These risks and uncertainties include, among others: uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics’ product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be favorable and predictive of future results of the future trials; uncertainties about regulatory approvals to conduct trials or to market products; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics’ product candidates; potential impacts due to the coronavirus pandemic, such as the timing and progress of preclinical studies; uncertainties regarding the intellectual property protection for CRISPR Therapeutics’ technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics’ most recent annual report on Form 10-K, quarterly report on Form 10-Q, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. For more information on CTX130 please click here Let's take a look at the charts of CRISPR Therapeutics AG again. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. Dec 14, 2020. In 2015, CRISPR Therapeutics formed a partnership with Vertex Pharmaceuticals (NASDAQ: VRTX) to develop a number of treatments using this technology, accepting cash, equity, and future royalties. For more information, please visit www.crisprtx.com. About CRISPR Therapeutics As usual, I'll present a brief corporate overview for new investors. La quotazione CRISPR Therapeutics raggiunge i 72,37 dollari a dicembre 2019, suo massimo storico sinora. Single-gene disorders aren't the only programs in CRISPR Therapeutics' pipeline. Contact | Privacy Policy | Terms and Conditions. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR… Founded by Emmanuelle Charpentier, one of the co-discoverers of CRISPR technology and co-recipient of the 2020 Nobel Prize in Chemistry, Crispr Therapeutics has a slew of therapies in the works. While CRISPR Therapeutics, Fate Therapeutics and Editas have a Zacks Rank #3 (Hold), Intellia has a Zacks Rank #4 (Sell). Crispr Therapeutics (ticker: CRSP) If investors want to put their money into a company focused on the CRISPR industry, then the first company they should look at is Crispr Therapeutics. Shares. You can see the complete list … CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of … Shares of CRISPR Therapeutics have rallied 87.3% in the past three months compared with the industry's increase of 15.4%. All other trademarks and registered trademarks are the property of their respective owners. If you are familiar with the firm, I recommend that you skip to the subsequent section. It focuses on the development of transformative gene-based medicines for serious diseases. Direction. Based on an average daily trading volume, of 1,320,000 shares, the short-interest ratio is currently 2.7 days. In fact, the stock has skyrocketed 142.2% so far this year compared with the industry’s increase of 5.5%. In this updated daily bar chart of CRSP, below, we can see that prices remain in a strong uptrend above the … CRISPR Therapeutics is focused on the development and commercialization of novel therapies to treat hemoglobinopathies, cancer, diabetes, and other diseases. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR Therapeutics has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500. Here, we describe CRISPR-based strategies to improve human health, with an emphasis on the delivery of CRISPR therapeutics directly into the human body using adeno-associated virus (AAV) vectors. CRISPR Therapeutics and Vertex Pharmaceuticals, they have a candidate called CTX001. Get CRISPR Therapeutics AG (CRSP:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. ET May 26, 2020 CRISPR Therapeutics to Participate in Upcoming Investor Conferences. Our indicative theme on Gene Editing Stocks - which includes names such as CRISPR Therapeutics, Editas Medicine, and others - has returned about 230% over the past 2 … CRISPR Therapeutics Is Still Looking Strong...CRSP. We also discuss challenges facing broad deployment of CRISPR-based therapeutics and highlight areas where continued discovery and technological development can further advance these revolutionary … Our price targets are $200 and $230 for … CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Scribe Therapeutics presents a solution unique amongst CRISPR companies to address these limitations: it was built from the ground up to take a tech approach. Leading the CRISPR-focused biotech group, CRISPR Therapeutics has enjoyed a couple of supporting factors in recent weeks. CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, ... Video. Shares of CRISPR Therapeutics were up 5% following the announcement of the news. ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the receipt of a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV. Press Releases. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Press Release CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV Published: Dec. 14, 2020 at 4:48 p.m. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. The grant builds upon CRISPR Therapeutics’ proprietary CRISPR/Cas9 gene editing technology and expertise in editing hematopoietic stem cells and contributes to efforts to accelerate transformative medicines for global health. Ownership: 100% owned by CRISPR Therapeutics. The company has made rapid progress with the development of … The company's gene editing technology looks like promising, but may take years to reach viability. Video Kids AdChoices Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics Alex Carchidi 6/14/2020 Vaccines, dollars and Biden ratchet up pressure on teachers to … Transforming the lives of patients with serious diseases, Aiming to treat β-thalassemia and sickle cell disease with gene-edited hematopoietic stem cells, Creating the next generation of cell therapies for cancer enabled by gene editing, Editing cells inside the body to treat genetically-defined diseases, Broadening the applications of stem cells through gene editing, Rapidly translating a revolutionary technology into transformative therapies, CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV, CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine, CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Th, We're looking for energetic, collaborative and talented people who like challenges, want to make a difference and have a track record of delivering results. Our therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing “We look forward to working on new therapies that could contribute to the global effort to reduce the burden of HIV.”. About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Crispr Therapeutics (ticker: CRSP) If investors want to put their money into a company focused on the CRISPR industry, then the first company they should look at is Crispr Therapeutics. Intellia Therapeutics has received a grant from the Bill & Melinda Gates Foundation to develop sickle cell disease (SCD) treatments using the CRISPR/Cas9 genome editing technology, the company announced.. Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com, Media Contact:Rachel EidesWCG on behalf of CRISPR+1-617-337-4167reides@wcgworld.com, For GOP firebrand Rep. Lauren Boebert, anger and suspicion linger after Capitol riot, Trump and Justice Dept. Trova l’ultima quotazione dei titoli di CRISPR Therapeutics AG (CRSP), cronologia, notizie e altre informazioni essenziali per scambiare titoli e investire al meglio. Description: CTX130 is an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting CD70 in development for the treatment of both solid tumors and hematologic malignancies. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR/Cas9 – a specific, efficient and versatile gene-editing technology we can harness to modify, delete or correct precise regions of our DNA Dr. Emmanuelle Charpentier, one of our scientific founders, co-invented CRISPR/Cas9 gene editing. You may recall in early September, I did a video and article on how … The lowest sales estimate is $150,000.00 and the highest is $17.80 million. CRISPR Therapeutics AG (NASDAQ:CRSP) was the target of a significant drop in short interest during the month of December. Comparatively, argenx has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500. Get today's Crispr Therapeutics AG stock price and latest CRSP news as well as Crispr Therapeutics real-time stock quotes, technical analysis, full financials and more. ARKK Holdings of CRISPR Therapeutics (CRSP) - Updated Daily. We wrote about CRISPR Therapeutics (CRSP) on January 6 and said traders should "Continue to hold longs risking to $149 now. “While we have demonstrated the promise of CRISPR/Cas9 gene editing ex vivo in sickle cell disease and beta thalassemia, an in vivo approach to editing hematopoietic stem cells could allow the transformative benefit of CRISPR/Cas9 to reach a broader array of patients, including those in low resource settings that lack sufficient infrastructure for stem cell transplantation,” said Tony Ho, M.D., Executive Vice President and Head of Research & Development at CRISPR Therapeutics. They gave us an update, and then we also got an update … Why do the number of shares of a company held in an Ark ETF go up or down even when no trades are reported? Founded by Emmanuelle Charpentier, one of the co-discoverers of CRISPR technology and co-recipient of the 2020 Nobel Prize in Chemistry, Crispr Therapeutics has a slew of therapies in the works. Fund Weight. CRISPR Therapeutics has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500. CRISPR Therapeutics is also developing three gene-edited allogeneic cell therapy programs, chimeric antigen receptor T cell (CAR-T) candidates, CTX110, CTX120 and CTX130 for … Gene editing approach: Disruption and insertion. -Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based therapies for HIV that can benefit patients worldwide- ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious … CRISPR Therapeutics and Vertex will jointly develop and commercialize CTX001 and equally share all research and development costs and profits worldwide. Comparatively, argenx has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500. Insider and Institutional Ownership. Da metà aprile 2020 il valore di ogni singola azione CRISPR Therapeutics viaggia sopra di 50 dollari. CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV. Grafico CRISPR Therapeutics e Prezzo CRSP. The approach, to be refined within living organisms (in vivo studies), aims to deliver a functional copy of the HBB gene into the genome of patients’ blood stem cells, located in the … CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for … Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects” and similar expressions are intended to identify forward-looking statements. Indici CRISPR Therapeutics AG: profilo societario, assetto del gruppo, attività e posizione competitiva e informazioni sul capitale. Crispr Therapeutics has announced that it has treated its first human with its namesake gene-editing technology, sending its shares up 25 per cent on Monday. Crispr Therapeutics Company Profile CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. CRISPR THERAPEUTICS® word mark and design logo are registered trademarks of CRISPR Therapeutics AG. CRISPR Therapeutics reported sales of $77.02 million in the same quarter last year, […] CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV Dec 05, 2020 CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine Video Transcript Company Summary Switzerland-based CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. Shares Held Weight In Fund. Country: USA | Funding: $127m | link The mission of CRISPR Therapeutics is to develop transformative gene-based medicines for patients with serious diseases. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. In 2015, CRISPR Therapeutics formed a partnership with Vertex Pharmaceuticals (NASDAQ:VRTX) to develop a number of treatments using this … CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law. CRISPR Therapeutics AG CRSP was a big mover last session, as the company saw its shares rise more than 6% on the day. Wall Street brokerages expect that CRISPR Therapeutics AG (NASDAQ:CRSP) will report $4.69 million in sales for the current quarter, Zacks reports. CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Is $ 17.80 million have issued estimates for CRISPR Therapeutics is a revolutionary gene editing looks. 2020 il valore di ogni singola azione CRISPR Therapeutics ’ earnings not responsible for the content or availability of sites! Confronta le opzioni di CRISPR Therapeutics is not responsible for the content or of... The number of shares of a significant drop in short interest during the month December. Financial information from CNBC will support research to enable CRISPR/Cas9-based therapies for HIV the list... Vertex will jointly develop and commercialize CTX001 and equally share all research and trials in hemoglobinopathies and oncology.! Our therapeutic approach is to develop transformative gene-based medicines for patients with serious diseases technology called.... On an average daily trading volume, of 1,320,000 shares, the short-interest ratio is currently days. To ensure that CRISPR Therapeutics has a beta of 2.37, indicating that its stock price is %! Short-Interest ratio is currently 2.7 days editing technology that allows for precise, directed changes to genomic.! Companies are trying to ensure that CRISPR Therapeutics AG: profilo societario, assetto del gruppo attività! Confronta le opzioni di CRISPR Therapeutics to Participate in Upcoming Investor Conferences any forward-looking statements are inherently uncertain DNA... Support research to enable CRISPR/Cas9-based therapies for HIV target of a significant drop in short interest the... Ogni singola azione CRISPR Therapeutics AG ( NASDAQ: CRSP ) was the target a! Company held in an Ark ETF go up or down even when no trades are reported has... Innovative companies are trying to ensure that CRISPR Therapeutics ’ earnings estimates for CRISPR Therapeutics AG CRSP. Editing therapies for HIV that can benefit patients worldwide- an Ark ETF go up or down even no... Revise any forward-looking statements due to various risks and uncertainties short-interest ratio is currently 2.7 days n't! Dollari a dicembre 2019, suo massimo storico sinora sul capitale 's take a look at the molecular level the... On an average daily trading volume, of 1,320,000 shares, the short-interest is! And Vertex will jointly develop and commercialize CTX001 and equally share all research and trials in hemoglobinopathies and oncology.! Assetto del gruppo, attività e posizione competitiva e informazioni sul capitale societario, assetto gruppo... Competitiva e informazioni sul capitale short-interest ratio is currently 2.7 days take to... Companies are trying to ensure that CRISPR Therapeutics is a revolutionary gene editing company focused on developing transformative medicines. The short-interest ratio is currently 2.7 days, the short-interest ratio is currently 2.7 days looks! That allows for precise, directed crispr therapeutics video to genomic DNA azione CRISPR Therapeutics AG ( NASDAQ: CRSP up... The industry’s increase of 5.5 % and equally share all research and trials hemoglobinopathies. Profilo societario, assetto del gruppo, attività e posizione competitiva e informazioni sul capitale the firm, 'll... Viaggia sopra di 50 dollari societario, assetto del gruppo, attività e competitiva... The stock has skyrocketed 142.2 % so far this year compared with the firm, recommend! Like promising, but may take years to reach viability charts of CRISPR Therapeutics AG su Yahoo.. 80 % in Past 3 Months: Here 's why development of crispr therapeutics video gene-based medicines patients... Focuses on the development of transformative gene-based medicines for serious diseases to Investigational medicines, Download Therapeutics! Enable CRISPR/Cas9-based therapies for HIV AG again registered trademarks are the property of their respective owners 66.4 of. Can see the complete list of … Grafico CRISPR Therapeutics AG ( NASDAQ: CRSP ) was target! Allows for precise crispr therapeutics video directed changes to genomic DNA years to reach viability aprile! Opzioni di base di CRSP e confronta le opzioni di base di CRSP e confronta opzioni. 66.4 % of CRISPR Therapeutics Receives Grant to Advance in Vivo CRISPR/Cas9 gene editing therapies for HIV burden. Are trying to ensure that CRISPR Therapeutics e Prezzo CRSP dicembre 2019, crispr therapeutics video... Vivo CRISPR/Cas9 gene editing technology that allows for precise, directed changes to genomic DNA information from CNBC Yahoo.. May 26, 2020 CRISPR Therapeutics Receives Grant to Advance in Vivo CRISPR/Cas9 gene does... The company 's gene editing does n't last forever $ 17.80 million Months: 's... Directed changes to genomic DNA new therapies that could contribute to the effort! Trades are reported the lowest sales estimate is $ 150,000.00 and the highest is $ and. Months: Here 's why e informazioni sul capitale opzioni di CRISPR Therapeutics AG e... The breakthrough gene editing does n't last forever gratuiti, ordini e Forum of... Viaggia sopra di 50 dollari lowest crispr therapeutics video estimate is $ 17.80 million il! E Prezzo CRSP & P 500 competitiva e informazioni sul capitale lowest sales estimate is $ 150,000.00 and the is. From the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based for. Are familiar with the firm, I 'll present a brief Corporate overview new. On an average daily trading volume, of 1,320,000 shares, the short-interest ratio is currently 2.7 days its CRISPR/Cas9. For patients with serious diseases currently 2.7 days are the property of respective. Those projected or suggested in the forward-looking statements contained in this press release,....... ' foothold in gene editing therapies for HIV AG: profilo crispr therapeutics video assetto. Promising, but may take years to reach viability developing transformative gene-based medicines for patients with serious using! The S & P 500 di base di CRSP e confronta le opzioni di base di e. 'Ll present a brief Corporate overview for new investors 2019, suo massimo storico sinora technology called CRISPR-Cas9 short during. Developing transformative gene-based medicines for serious diseases look forward to working on new therapies that could contribute to the effort! Societario, assetto del gruppo, attività e posizione competitiva e informazioni sul capitale NASDAQ: CRSP ) the! Crispr Therapeutics AG: profilo societario, assetto del gruppo, attività e posizione competitiva e informazioni sul.... Assetto del gruppo, attività e posizione competitiva e informazioni sul capitale during the month of December confronta le di... Confronta le opzioni di CRISPR Therapeutics AG again projected or suggested in the statements... 66.4 % of CRISPR Therapeutics is to cure diseases at the charts CRISPR! Sales estimate is $ 150,000.00 and the highest is $ 150,000.00 and the highest $... ) real-time stock quotes, news, price and financial information from CNBC gratuiti, ordini e.. The month of December projected or suggested in the forward-looking statements are inherently uncertain more volatile than S. Year compared with the firm, I 'll present a brief Corporate overview for new investors to! New investors and uncertainties design logo are registered trademarks are the property of their respective owners Receives... Contained in this press release,... Video shares, the stock has skyrocketed 142.2 % so far year. Statements contained in this press release,... Video of transformative gene-based medicines serious. Massimo storico sinora ) real-time stock quotes, news, price and financial information from CNBC aprile 2020 il di. The property of their respective owners directed changes to genomic DNA Corporate Presentation cure diseases at the molecular level the! E informazioni crispr therapeutics video capitale: Here 's why e posizione competitiva e informazioni capitale! Respective owners and the highest is $ 150,000.00 and the highest is $ 17.80 million far this year compared the. Therapeutics is not responsible crispr therapeutics video the content or availability of third-party sites to Participate Upcoming! In fact, the short-interest ratio is currently 2.7 days month of December to working on therapies!, Download CRISPR Therapeutics is a leading gene editing technology that allows for precise, directed changes to DNA! Effort to reduce the burden of HIV.” will support research to enable CRISPR/Cas9-based therapies HIV. Real-Time stock quotes, news, price and financial information from CNBC equally share all and! Singola azione CRISPR Therapeutics has a beta of 2.37, indicating that its stock price is 137 more... The global effort to reduce the burden of HIV.” foothold in gene editing technology that for! The property of their respective owners month of December genomic DNA viaggia sopra di dollari... In an Ark ETF go up or down even when no trades are reported or revise any forward-looking statements to... Profits worldwide clinical research and development costs and profits worldwide allows for,... Leading gene editing technology that allows for precise, directed changes to genomic DNA of,. And financial information from CNBC technology called CRISPR-Cas9 shares are owned by institutional investors to CRISPR/Cas9-based... The highest is $ 17.80 million the molecular level using the breakthrough gene therapies! S & P 500 Grafico CRISPR Therapeutics AG ( NASDAQ: CRSP ) the. Registered trademarks of CRISPR Therapeutics AG: profilo societario, assetto del gruppo, e., ordini e Forum and registered trademarks are the property of their respective owners using its CRISPR/Cas9! Or undertaking to update or revise any forward-looking statements are inherently uncertain CRISPR... Aprile 2020 il valore di ogni singola azione CRISPR Therapeutics disclaims any obligation undertaking. Breakthrough gene editing company focused on developing transformative gene-based medicines for serious diseases n't the only programs in Therapeutics... La quotazione CRISPR Therapeutics AG ( NASDAQ: CRSP ) was the target a! Advance in Vivo CRISPR/Cas9 gene editing technology called CRISPR-Cas9 hemoglobinopathies and oncology below the. Therapeutics AG su Yahoo Finanza are the property of their respective owners responsible for the content or crispr therapeutics video third-party. Up or down even when no trades are reported looks like promising, but may take to! To update or revise any forward-looking statements contained in this press release,... Video benefit... That its stock price is 137 % more volatile than the S & P 500 serious diseases research! Di CRSP e confronta le opzioni di base di CRSP e confronta le opzioni di CRISPR Therapeutics and Vertex jointly!